AssetMark Inc
RKDA icon

AssetMark Inc’s Arcadia Biosciences RKDA Stock Holding History

AssetMark Inc’s Portfolio RKDA Stock Details RKDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7 Hold
5
– – ﹤0.01% 3433
2025
Q4 		$10 Hold
5
– – ﹤0.01% 3361
2025
Q3 		$17 Hold
5
– – ﹤0.01% 3170
2025
Q2 		$22 Hold
5
– – ﹤0.01% 2984
2025
Q1 		$15 Hold
5
– – ﹤0.01% 2606
2024
Q4 		$30 Hold
5
– – ﹤0.01% 2569
2024
Q3 		$14 Buy
+5
New +$14 ﹤0.01% 2241

Other funds holding RKDA

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

AssetMark Inc's RKDA Position: Q1 2026 in Review

AssetMark Inc held its Arcadia Biosciences (RKDA) position steady in Q1 2026 at 5 shares worth $7. The position accounts for ﹤0.01% of the portfolio, ranked #3433.

AssetMark Inc first reported a position in RKDA in Q3 2024 and has held it in 7 quarters since. The position peaked at $30 in Q4 2024. 16 funds tracked by Wall St. Rank hold RKDA as of Q1 2026.

  • AssetMark Inc held 5 shares of Arcadia Biosciences worth $7 as of Q1 2026.
  • AssetMark Inc left its Arcadia Biosciences share count unchanged in Q1 2026.
  • Arcadia Biosciences made up ﹤0.01% of AssetMark Inc's portfolio in Q1 2026, its #3433 holding.
  • AssetMark Inc first reported a position in Arcadia Biosciences in Q3 2024 and has held it in 7 quarters since.
  • AssetMark Inc's Arcadia Biosciences position peaked at $30 in Q4 2024.
  • 16 funds tracked by Wall St. Rank held Arcadia Biosciences as of Q1 2026.

Based on AssetMark Inc's 13F filing for Q1 2026, filed 6 May 2026.